Study finds GLP1 semaglutide reduced systemic inflammation within weeks, before substantial weight loss, and lowered MACE (major adverse cardiovascular events) risk even without weight loss
Study finds GLP1 semaglutide reduced systemic inflammation within weeks, before substantial weight loss, and lowered MACE (major adverse cardiovascular events) risk even without weight loss